Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2020 | UK CAR-T: changing the landscape of lymphoma treatment

Andrea Kuhnl • 15 Jun 2020
EHA 2020
Lymphoma CAR-T

Andrea Kuhnl, MD, King’s College Hospital, London, United Kingdom, discusses the impact of CAR T-cell therapy on the treatment of lymphoma patients in the UK as well as potential pitfalls associated with their use. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Andrea Kuhnl

Widespread adoption of CAR-T therapy in the UK: fostering specialist networks
1:02
Widespread adoption of CAR-T therapy in the UK: fostering specialist networks
Andrea Kuhnl • 18 Jun 2025
The use of early PET responses to predict the risk of relapse after second-line axi-cel in LBCL
1:14
The use of early PET responses to predict the risk of relapse after second-line axi-cel in LBCL
Andrea Kuhnl • 18 Jun 2025
The efficacy and feasibility of using radiotherapy as a bridge to CAR-T in patients with lymphoma
1:27
The efficacy and feasibility of using radiotherapy as a bridge to CAR-T in patients with lymphoma
Andrea Kuhnl • 18 Jun 2025
Experience with the RESTART protocol: integrating radiotherapy into the peri-CAR-T setting for LBCL
1:33
Experience with the RESTART protocol: integrating radiotherapy into the peri-CAR-T setting for LBCL
Andrea Kuhnl • 18 Jun 2025

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Andrea Kuhnl • 6 Dec 2025
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
2:10
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
Andrea Kuhnl • 8 Dec 2025
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
2:42
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
Andrea Kuhnl • 8 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Andrea Kuhnl • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals